Cargando…
Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed malignancies worldwide with poor prognosis and tends to be hypervascular. Aberrant expression of the vascular endothelial growth factor 2 (VEGFR‐2) has been implicated in the progression of HCC and represents a valid target for ant...
Autores principales: | Yang, Chaoxu, Qin, Shukui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6144148/ https://www.ncbi.nlm.nih.gov/pubmed/30109780 http://dx.doi.org/10.1002/cam4.1664 |
Ejemplares similares
-
Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma
por: Xia, Yujia, et al.
Publicado: (2021) -
miR‐206 inhibits the growth of hepatocellular carcinoma cells via targeting CDK9
por: Pang, Chi, et al.
Publicado: (2017) -
Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence
por: Shi, Ji‐Hua, et al.
Publicado: (2019) -
FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma
por: Zhong, Cheng‐Qian, et al.
Publicado: (2018) -
NFATc1 is a tumor suppressor in hepatocellular carcinoma and induces tumor cell apoptosis by activating the FasL‐mediated extrinsic signaling pathway
por: Xu, Sanrong, et al.
Publicado: (2018)